Skip to main content

Table 2 Gastrointestinal manifestations of participants at baseline of trial

From: Efficacy of atypical antipsychotics in the treatment of fecal incontinence in children and adolescents: a randomized clinical trial

variable

All subjects

Placebo

(n = 67)

Risperidone

(n = 69)

P

value d

History of seizures

   

Psychiatric disorder

Yes

1(1.4)

1(2.9)

0(0.0)

-

No

0(0.0)

0(0.0)

0(0.0)

0.52

Thyroid disorder

   

Psychiatric disorder

Yes

0(0.0)

0(0.0)

0(0.0)

-

No

67(100.0)

35(100.0)

32(94.1)

0.39

Abdominal surgery

   

Psychiatric disorder

Yes

1(1.4)

1(2.8)

0(0)

0.46

No

1(1.4)

1(2.8)

0(0)

0.46

Constipation

   

Psychiatric disorder

Yes

47(68.1)

22(62.8)

25(73.5)

0.36

No

43(64.1)

21(60.0)

22(64.7)

0.31

Hemorrhoids

   

Psychiatric disorder

Yes

5(7.24)

5(14.2)

0(0.0)

0.025

No

4(5.97)

3(8.5)

1(2.94)

0.34

Fissure

   

Psychiatric disorder

Yes

15(21.7)

8(22.8)

7(20.5)

0.47

No

11(16.4)

4(11.4)

7(20.5)

0.20

Hard stools

    

Psychiatric disorder

Yes

45(65.2)

22(62.8)

23(67.6)

0.56

No

41(61.1)

19(54.2)

22(64.7)

0.16

Compact feces

   

Psychiatric disorder

Yes

43(62.3)

21(60.0)

22(64.7)

0.56

No

40(59.7)

20(57.1)

20(58.8)

0.46

  1. Data are n (%).
  2. fP values have been calculated by chi-square tests between groups.